Loading ATI detail
Loading ticker data...
Loading ATI detail
ATI Inc. manufactures and sells specialty materials and components worldwide. The company operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S).
The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products, and titanium products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets.
The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.
Chart data unavailable
ATI (ATI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how ATI (ATI) and Rolls-Royce Holdings PLC (RYCEY) have performed compared to their sector so far this year.
ATI (ATI) closed the most recent trading day at $159.63, moving +2.07% from the previous trading session.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ATI (ATI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Watts Water Technologies and ATI both benefit from real, physical demand tied to AI infrastructure and aerospace. Both companies have strong fundamentals, but still come with risks that require patience and a long-term mindset.
DALLAS, April 2, 2026 /PRNewswire/ -- ATI (NYSE: ATI) has scheduled the live webcast for its first quarter 2026 earnings conference call on Thursday, April 30, 2026, at 7:30 a.m. CT (8:30 a.m.
Assenagon Asset Management S.A. lessened its position in ATI Inc. (NYSE: ATI) by 61.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,818 shares of the basic materials company's stock after selling 41,815 shares during the quarter. Assenagon Asset Management S.A.'s holdings
The latest trading day saw ATI (ATI) settling at $135.5, representing a -3.51% change from its previous close.
ATI (ATI) possesses solid growth attributes, which could help it handily outperform the market.
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided additional results from its Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of ITK and Janus kinase 3 (JAK3), presented in an electronic poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
ATI Inc. ATI and Carpenter Technology Corporation CRS are two prominent players in the specialty metals space, with a focus on high-performance alloys for aerospace, defense and industrial applications.
Here is how ATI (ATI) and RTX (RTX) have performed compared to their sector so far this year.
WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), will be available during the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. The poster will include results not previously reported from Aclaris' Phase 2a trial in patients with moderate-to-severe atopic dermatitis (AD).
